FMP
HilleVax, Inc.
HLVX
NASDAQ
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
2.09 USD
0.01 (0.478%)
Valuation Date:
Jan 3, 2025 9:00 PM
Share Price on Valuation Date
$2.09
Stock Beta
0.773
Shares Outstanding
49806070